Post by omstem on Jul 4, 2016 22:48:05 GMT
Interesting. He is appointed as Director of Cynata, An Australian Stem Cell Company. Their strength seem to be in the production of cells with their proprietary technology though they claim to be on the clinical side too.
Makes me wonder if I should start a position in Cynata at the current SP and MC levels because I feel that this could be a candidate for sale in future. Whether investors make money or not depends upon the PPS levels they have invested in.
While researching this company I found some interesting reading material from Raghuram Selvaraju, though his hit ratio is not that impressive.
Thanks.
Makes me wonder if I should start a position in Cynata at the current SP and MC levels because I feel that this could be a candidate for sale in future. Whether investors make money or not depends upon the PPS levels they have invested in.
While researching this company I found some interesting reading material from Raghuram Selvaraju, though his hit ratio is not that impressive.
Thanks.
